Zemdri Generic Name & Formulations
Mechanism of Action
Plazomicin is an aminoglycoside that acts by binding to bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis. Plazomicin has concentration-dependent bactericidal activity as measured by time kill studies.
Zemdri Dosage and Administration
Zemdri Boxed Warnings
Assess CrCl in all patients prior to initiation, daily during therapy, and esp. in those at increased risk of nephrotoxicity (eg, renal impairment, elderly, concomitant potentially nephrotoxic drugs). Patients with CrCl ≥15–<90mL/min: monitor and maintain plasma trough level <3mcg/mL. Risk for ototoxicity (eg, family history of hearing loss, renal impairment, taking higher doses and/or prolonged use, or with certain mitochondrial DNA variants); consider alternative therapies. Underlying neuromuscular disorders (eg, myasthenia gravis) or concomitant neuromuscular blockers: monitor for adverse reactions. Discontinue if allergic reaction occurs. Renal impairment: monitor and adjust dose (see Adult). Elderly: monitor. Pregnancy: fetal harm can occur. Nursing mothers.
Renal. Half-life: 3.5 hours.
Zemdri Adverse Reactions
Zemdri Clinical Trials
Zemdri Patient Counseling